{"id":"heptobarbital","rwe":[{"pmid":"14249930","year":"1964","title":"[HEPTOBARBITAL].","finding":"","journal":"Ceskoslovenska farmacie","studyType":"Clinical Study"}],"tags":[{"label":"heptobarbital","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"mephebarbital","offLabel":[],"synonyms":["phenylmethylbarbituric acid","heptobarbital","mephebarbital","methylphenylbarbital"],"timeline":[],"approvals":[],"brandName":"Mephebarbital","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"heptobarbital","explanation":"Imagine your brain is like a busy city with many different streets and intersections. Neurotransmitters are like traffic signals that help control the flow of information between different parts of the brain. Mephebarbital helps to amplify the signal from these traffic lights, making it easier for the brain to relax and calm down.","oneSentence":"Mephebarbital works by enhancing the activity of neurotransmitters in the brain, such as GABA, to produce a calming effect.","technicalDetail":"Mephebarbital is a barbiturate that acts as a GABA receptor agonist, increasing the frequency of chloride channel opening and resulting in hyperpolarization of neurons, which leads to a decrease in neuronal excitability and a calming effect."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3815","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=heptobarbital","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:52:43.272007","biosimilars":[],"competitors":[],"genericName":"heptobarbital","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"GFR227X6YY","CHEBI":"CHEBI:134900","UMLSCUI":"C0304360","PUBCHEM_CID":"66160","SNOMEDCT_US":"82131004"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"1964 Dec","pmid":"14249930","title":"[HEPTOBARBITAL].","journal":"Ceskoslovenska farmacie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Mephebarbital, also known as heptobarbital, is a small molecule drug in the barbiturate class. Its exact target and mechanism of action are unknown, but it is believed to work by enhancing the activity of neurotransmitters in the brain. Mephebarbital is not FDA-approved for any indications and its commercial status is unclear. As a barbiturate, it carries significant risks of dependence, tolerance, and overdose. Further research is needed to fully understand its pharmacology and potential therapeutic applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}